BR112022017401A2 - Opicapona micronizada - Google Patents

Opicapona micronizada

Info

Publication number
BR112022017401A2
BR112022017401A2 BR112022017401A BR112022017401A BR112022017401A2 BR 112022017401 A2 BR112022017401 A2 BR 112022017401A2 BR 112022017401 A BR112022017401 A BR 112022017401A BR 112022017401 A BR112022017401 A BR 112022017401A BR 112022017401 A2 BR112022017401 A2 BR 112022017401A2
Authority
BR
Brazil
Prior art keywords
opicapone
micronized
relates
products
methods
Prior art date
Application number
BR112022017401A
Other languages
English (en)
Inventor
VASCONCELOS Teófilo
Russo Domenico
Rita Gonçalves Da Cruz Ramos Pires Ana
Maria Correia Dias Sonia
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003705.7A external-priority patent/GB202003705D0/en
Priority claimed from GBGB2007814.3A external-priority patent/GB202007814D0/en
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of BR112022017401A2 publication Critical patent/BR112022017401A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

OPICAPONA MICRONIZADA. A presente invenção refere-se a produtos farmacêuticos micronizados de opicapona cristalina com uma percentagem do número de aglomerados em feixe inferior ou igual a 30%. A invenção também se refere a métodos de produção destes produtos farmacêuticos micronizados e o seu uso na melhoria da biodisponibilidade de opicapona no tratamento de doença de Parkinson. Além disso, a invenção proporciona métodos para calcular a distribuição de tamanho de partícula primária e teor de aglomerados de tais produtos.
BR112022017401A 2020-03-13 2021-03-12 Opicapona micronizada BR112022017401A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2003705.7A GB202003705D0 (en) 2020-03-13 2020-03-13 Micronised opicapone
GBGB2007814.3A GB202007814D0 (en) 2020-05-26 2020-05-26 Micronised opicapone
PCT/PT2021/050006 WO2021182981A1 (en) 2020-03-13 2021-03-12 Micronised opicapone

Publications (1)

Publication Number Publication Date
BR112022017401A2 true BR112022017401A2 (pt) 2022-10-18

Family

ID=75143706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017401A BR112022017401A2 (pt) 2020-03-13 2021-03-12 Opicapona micronizada

Country Status (9)

Country Link
US (1) US20230147302A1 (pt)
EP (1) EP4117637A1 (pt)
JP (1) JP2023517690A (pt)
KR (1) KR20220154182A (pt)
CN (1) CN115335036A (pt)
AU (1) AU2021235850A1 (pt)
BR (1) BR112022017401A2 (pt)
CA (1) CA3174918A1 (pt)
WO (1) WO2021182981A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Also Published As

Publication number Publication date
WO2021182981A1 (en) 2021-09-16
KR20220154182A (ko) 2022-11-21
EP4117637A1 (en) 2023-01-18
US20230147302A1 (en) 2023-05-11
CA3174918A1 (en) 2021-09-16
JP2023517690A (ja) 2023-04-26
AU2021235850A1 (en) 2022-10-06
CN115335036A (zh) 2022-11-11

Similar Documents

Publication Publication Date Title
BRPI0412153A (pt) métodos para produzir um anticorpo que reage cruzado com produtos de gene kir2dl múltiplos e que neutraliza a atividade inibidora de tais kirs, e para avaliar a toxicidade de um anticorpo, e, anticorpo, fragmento de anticorpo ou um derivado de anticorpo
US8334131B2 (en) Formulations for promoting stem cell nutrition
CN104188999A (zh) 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法
BR112022017401A2 (pt) Opicapona micronizada
CN103768123A (zh) 一种中药组合物及其制备方法
US20220273686A1 (en) Pharmaceutical composition for producing safe amount of nitric oxide and use thereof
BR112022020776A2 (pt) Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3
Stefanowski et al. The effect of vitamin D3 deficiency on the severity of depressive symptoms. Overview of current research
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
Liu et al. Effect of nano‐hydroxyapatite‐coated magnetic nanoparticles on axonal guidance growth of rat dorsal root ganglion neurons
Zhang et al. Magnesium and osteoarthritis: from a new perspective
BR112014026439A2 (pt) comprimidos revestidos e produção dos mesmos
Nadaf et al. Evaluation of Prosopis africana seed gum as an extended release polymer for tablet formulation
Taherkhani et al. Identification of potential glucosyltransferase inhibitors from cinnamic acid derivatives using molecular docking analysis: a bioinformatics study
KR20160137528A (ko) 크레아틴, 오메가-3 지방산 및 시티콜린의 조합
BR112012022209A2 (pt) composições farmacêuticas compreendendo monoterpenos
CN101947233A (zh) 用于治疗畜禽呼吸道疾病的复方药物组合物及其可溶性粉
Chawan et al. Analysis of price variation amongst different formulations of anxiolytic drugs available in Indian market
CN105963317A (zh) 一种具有增加骨密度功能的药物组合物
Sarumathy et al. Efficacy and safety of oral glutamine in radiation induced oral mucositis in patients with head and neck cancer
Rajshekhar et al. Efficacy of vitamin D supplementation in the treatment of severe pneumonia in children aged less than five years
El–Alfy et al. Genotoxic effect of methotrexate on bone marrow chromosomes and DNA of male albino mice (Mus musculus)
Brunetti et al. Inhibitory effects of Euphorbia tirucalli latex on murine B16/F10 melanoma cells and lung metastasis
BR112022008397A8 (pt) Sulfato de condroitina com baixo peso molecular, composição, método de preparação e uso do mesmo
JP2021187826A (ja) 免疫力向上及び腸管機能調整の機能を有するビフィドバクテリウム・アニマリスｂｚ１１複合菌剤